School of Medicine; Department of Urology
Female Urogenital Diseases and Pregnancy Complications | Male Urogenital Diseases | Urology
Overactive bladder is a highly prevalent disorder with a significant impact on quality of life. Antimuscarinic agents are commonly used, but persistence is limited due to unsatisfactory efficacy and/or tolerability. Mirabegron is the first beta-3 adrenoceptor agonist approved for the treatment of overactive bladder syndrome. This paper reviews the pharmacology, mechanism of action, efficacy, and safety of mirabegron. A PubMed search of all English articles pertaining to mirabegron was performed. An alternative to antimuscarinics, mirabegron has a unique mechanism, improves overactive bladder symptoms and quality of life, and has limited adverse effects and few contraindications.
beta-3 agonist, incontinence, mirabegron, overactive bladder
Rights and Permissions
This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php.
DOI of Published Version
Res Rep Urol. 2013 Oct 25;5:147-57. doi: 10.2147/RRU.S38792. Link to article on publisher's site
Research and reports in urology
Lee R, Bamberger MH, Ellsworth P. (2013). Impact of mirabegron extended-release on the treatment of overactive bladder with urge urinary incontinence, urgency, and frequency. University of Massachusetts Medical School Faculty Publications. https://doi.org/10.2147/RRU.S38792. Retrieved from https://escholarship.umassmed.edu/faculty_pubs/771
Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial 3.0 License